Summary: PARP inhibitors (PARPi) are used as a first-line treatment option for cancers with BRCA1/2 mutations, yet a significant number of patients show a limited response to these agents. In the present study, Lei and colleagues demonstrate that PARPi promote increased ferroptosis sensitivity and this can be exploited therapeutically to improve the response to PARPi, marking an important therapeutic concept to exploit ferroptosis-based strategies in clinical settings. See related article by Lei et al., p. 1476 (2).

中文翻译：

---

铁：打破 PARPi 阻力的秘密成分


摘要：PARP 抑制剂 (PARPi) 被用作 BRCA1/2 突变癌症的一线治疗选择，但大量患者对这些药物的反应有限。在本研究中，Lei 及其同事证明 PARPi 促进铁死亡敏感性的增加，这可以在治疗上利用来改善对 PARPi 的反应，这标志着在临床环境中利用基于铁死亡的策略的重要治疗概念。参见 Lei 等人的相关文章，第 17 页。 1476（2）。